Navigation Links
Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
Date:5/21/2013

  However, an estimated 10% to 20% of asthmatic patients are less than optimally controlled despite existing therapies.  Moderate-to-severe asthma can negatively impact the lives of patients and is associated with a high burden to society both in terms of direct costs of medical care and prescription drugs, as well as loss of productivity.  Moderate-to-severe asthma is recognized as a heterogeneous disease; the Th2 inflammation pathway is believed to play a role in disease pathogenesis in approximately 50% of these patients.  It is estimated that approximately 25 million people in the United States are known to have asthma.  The worldwide estimates are between 235-300 million people, with 180,000 deaths annually.

About SanofiSanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs.  Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.  Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

About Regeneron Pharmaceuticals, Inc.Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.

Sanofi Forwar
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
2. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
3. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
4. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
5. NextBio Announces Translational Medicine Partnership with Sanofi
6. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
7. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
8. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
9. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
10. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
11. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... , July 30, 2015  Cleveland Clinic President ... keynote address last month that industry is compelled to ... to gain the efficiencies—and develop the transformational innovations -- ... Barsoum,s comments were preceded by Doug Kohrs , ... OMTEC moderator, who stressed that industry must add "episode ...
(Date:7/30/2015)... YORK , July 30, 2015 /PRNewswire/ ... a new research report with market overview, ... share, forecast, porter analysis, recent developments, competitive ... Global Industry Insight: Biosensors Market Development ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778 ) ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... WOONSOCKET, R.I., Dec. 11 CVS Caremark (NYSE: ... Senior Vice President and Chief Human Resources Officer, effective January ... announced his retirement. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090226/NE75914LOGO ) ... Caremark, has more than 30 years of human resources experience. ...
... , OXFORD, England, December 11 ... Ii Clinical Results With cat,Allergy T-cell Vaccine , ... Into,Late-Stage Development , Circassia Ltd, a ... completed a GBP15 million ($25 million),fundraising. The investment round, which ...
Cached Medicine Technology:CVS Caremark Names New Chief Human Resources Officer 2Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round 2
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia and Peach State ... Girl Scout "Be a Friend First" program. Representatives from Peach State Health Plan presented ... State Health Plan and our parent company, Centene Corporation, are dedicated to raising anti-bullying ...
(Date:7/31/2015)... Seattle, WA (PRWEB) , ... July 31, 2015 , ... ... rapidly transforming the way we treat aging diseases. , BioViva announces it has ... to treat patients with Alzheimer’s Disease (AD) and find a cure. MaxLife will grant ...
(Date:7/31/2015)... ... , ... The Heart Fit Clinic has increased a patient's fitness level 60 ... 150 beats versus 100 beats, this is a big deal," says Diamond Fernandes, director ... to patients with heart disease," he adds. People with angina are able to do ...
(Date:7/31/2015)... York, NY (PRWEB) , ... July 31, 2015 , ... ... kidney disease, according to a study published today in Nature Communications and led by ... conducted in mice, suggests that variations in the gene RTN1 led to greater production ...
(Date:7/31/2015)... ... , ... Indosoft, Inc., is pleased to announce a major update to its ... contact center ACD system for Asterisk-based call centers . The new features make ... to the agent only when wanted, and allows for validation of data as the ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2
... Healthy Directions, LLC, is proud to announce the launch of searchjointpain.com, a ... conditions and solutions. , ... Potomac, MD (PRWEB) February 27, 2009 -- ... to announce the launch of searchjointpain.com , a new informational Web ...
... LLC announces the implementation of its rehabilitation software by ... for Southeast Missouri Hospital, a 269-bed regional medical complex ... includes functionality for electronically managing therapy documentation, scheduling, referrals, ... ...
... of the most expensive benefit claims made by members. , ... Melbourne, ... complex bowel surgery heads the annual Medibank Private "Chart Toppers" list of ... of the fund., , ,The bowel surgery claim, costing 20 per cent ...
... Directors Recommends Shareholders Accept the A$318 Million Offer, ... Company Offers Strong Technology Platform and Phase II ... 27 Cephalon, Inc . (Nasdaq: ... subsidiary, Cephalon International Holdings, Inc., intends to make ...
... Asian AffiliateNEW YORK and SINGAPORE, Feb. 26 ... services, has signed an affiliation agreement with Parkway ... based in Singapore and a subsidiary of Parkway ... programs throughout Asia. Under the agreement, ParkwayHealth will ...
... affects approximately 250,000 people in the United States, occurs ... or fatty tissue and loses function. While scientists have ... curing the disease, another part of the mystery has ... University of Missouri scientist and his team have identified ...
Cached Medicine News:Health News:Healthy Living Network Announces Launch of New Joint Pain Web Site 2Health News:Southeast Missouri Hospital Implements Chart Links Rehabilitation Software for Therapists 2Health News:Southeast Missouri Hospital Implements Chart Links Rehabilitation Software for Therapists 3Health News:Health Insurance Claims Top $2 Million Mark 2Health News:Health Insurance Claims Top $2 Million Mark 3Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 2Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 3Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 4Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 5Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 6Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 7Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 8Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 9Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 10Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 11Health News:Cephalon Launches Takeover Offer for Australian Biotechnology Company, Arana Therapeutics 12Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 2Health News:U.S. Preventive Medicine(R), ParkwayHealth Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services in Asia 3Health News:Muscular dystrophy mystery solved; Mizzou scientist moves closer to MD solution 2
The Auto Suture™ EEA™ 34mm reusable stainless steel sizer has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
... synthesized in the parafollicular C-cells of the ... granules. The major action of calcitonin is ... osteoclast activity, resulting in decreased mobilization of ... most evident in conditions associated with high ...
Validated by decades of research and clinical experience, HFA is the accepted standard of care in glaucoma diagnosis and management. With HFA you can feel confident you're providing the best possible...
Erbium Laser with Sapphire Erbium Handpiece for Dermatological and Cosmetic Surgery...
Medicine Products: